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Vasopeptidase inhibitionAbstract Introduction: Ularitide is a synthetic form of renally derived natriuretic peptide (NP),
urodilatin. Omapatrilat (OMA) is a Vasopeptidase inhibitor (VPI), acting by dual inhibition of both
angiotensin-converting enzyme (ACE) and neutral endopeptidase 24.11 (NEP), which degrades the
NPs. Ularitide and OMA underwent evaluation for the management of hypertension and heart fail-
ure (HF).
Aim: This study aimed to address the effect of ularitide and OMA in aortocaval fistula (ACF) –
induced congestive heart failure (CHF) in rats under various conditions of compensation (of clinical
severity).
Experimental protocol: Volume-overload CHF was induced in male albino rats by creating an
infrarenal ACF. One week after fistula induction, ACF rats were randomized to compensated
(Com) and decompensated (Decom) ACF groups and each further subdivided into ACF, ularitide
and OMA/ularitide treated ACF groups. Sham was used as control. All treatment protocols were
started one week after infrarenal ACF induction and continued for further two weeks. Three weeks
after shunt induction, all animals were underwent assessment of cardiorenal and humoral functions.
Renal outcome was measured by glomerular filtration rate (GFR), fractional excretion of sodium
(FNa), absolute urinary sodium excretion (UNaV), urine volume, plasma cystin C level and urinary
cyclic 30, 50-guanosine monophosphate (cGMP). The humoral function was assessed by plasma
renin activity (PRA), angiotensin II (Ang II), Aldosterone, and cGMP. Cardiac outcome was
assessed by plasma atrial natriuretic peptide (ANP), N-terminal pro–brain natriuretic peptide
(NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) while total and relative heart, lung
and liver weights were recorded.rilat, on
doi.org/
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10.1016/j.ajme.2016.05.005Results: Induction of AC shunt was associated with deteriorated renal and excretory functions,
activation of renin angiotensin aldosterone system (RAAS), elevated ANP with renal resistance
to ANP, (NT-proBNP) and (cTnT), pulmonary and systemic congestion and marked cardiac hyper-
trophy. These changes were exacerbated in Decom-ACF.
Ularitide treatment of ACF rats was associated with natriuresis, diuresis, enhanced GFR with
RAAS inhibition. This effect was evident in Com-ACF, maximized by OMA but attenuated in
Decom-ACF, restored by OMA treatment. Ularitide/OMA treatment had antihypertrophic, decon-
gestant effect with preserved renal function, resulted in a marked improvement of animals’ survival.
Conclusion: OMA potentiates the cardiorenal actions of ularitide in ACF-induced Com CHF and
restoring its effect in Decom ACF, by simultaneously inhibiting ACE and NEP. OMA and ularitide
could provide an effective therapeutic strategy for CHF.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Congestive heart failure (CHF) is a major, expanding public
health problem with a poor prognosis and the most common
cause for hospitalization of elderly patients. CHF is a syn-
drome characterized by myocardial structural and functional
impairment and a severe disturbance of body fluid balance.1
The immediate clinical goal in managing HF is to provide
symptom relief and to stabilize the patients’ hemodynamics.
Unfortunately, these treatments often only provide symp-
tomatic relief and temporarily increased risk of renal deteriora-
tion and impede disease progression.2 Thus; the search for
agents that improve HF signs and symptoms and preserve
renal function without increasing mortality risk has been an
area of ongoing research.
Volume overload represents a clinically relevant condition
leading to HF, for example in aortic or mitral valve insuffi-
ciency. The rat model of chronic HF due to volume overload
induced by aortocaval fistula (ACF) is simple, reproducible
and well-characterized model of CHF, sharing many similari-
ties with the natural course of human HF.3 This artificial
AC shunt causes a marked increase in venous return (VR)
and cardiac output (CO) that triggers compensatory, initially
asymptomatic cardiac hypertrophy. With persistent hemody-
namic overload and redistribution of CO, it leads to gradual
transition from asymptomatic into the decompensated phase,
marked renal and neurohumoral changes that closely mimic
those found in patients with advanced HF. These include
reduced renal blood flow and GFR, urinary salt and water
retention, activation of the RAAS, and increased secretion
of, but blunted response to, ANP.4
Ularitide (urodilatin) is a natriuretic peptide (NP) composed
of 32 amino acid residues [ANP-(95–126)] with a primary struc-
ture similar to ANP (99–126) and it was isolated from human
urine.5 Similar to ANP, ularitide binds to the natriuretic
peptide-A receptor (NPR-A), with similar affinities, and is
cleared by the natriuretic peptide-C receptor (NPR-C) and
degraded by the ectoenzyme neutral endopeptidase 24.11 (NEP).5
Ularitide is more active than ANP as a natriuretic agent
and more resistant than ANP to degradation by NEP, as it
exhibits an N-terminal extension by four amino acids com-
pared with ANP.5
After synthesis in the distal tubular cells, urodilatin is lumi-
nally secreted and binds further downstream in the inner
medullary collecting duct to NPR-A, mediating its effects viait RE Eﬀect of the renal natriuretic pept
estive heart failure in rats (Ularitide/Oincreasing intracellular cyclic 30, 50-guanosine monophosphate
(cGMP) levels.6
Urodilatin administered intravenously (IV) to rats, dogs or
healthy volunteers exhibits hemodynamic as well as diuretic
and natriuretic effects.5
Omapatrilat (OMA), is a potent oral, long-acting dual met-
alloprotease inhibitor, the most extensively studied, to date.7
OMA has selective and competitive inhibitory activity of
both angiotensin-converting enzyme (ACE) with subsequent
suppression of RAAS and (NEP), which degrades natriuretic
and vasodilator peptides such as adrenomedullin and bradyki-
nin, heightening activity of these endogenous vasodilator sys-
tems leading to more potent hemodynamic and renal effects
and improving myocardial function than the selective inhibi-
tion of the same enzymes.8
The present study was carried out to evaluate the effect of
ularitide and OMA in albino rats with the (ACF) model of
high-output HF and exploring the differential response in
compensated versus decompensated stage and the possible
underlying mechanisms.
2. Materials and methods
2.1. Experimental animals
The experimental protocols were approved by the Ethical
Committee for Animal Experimentation at the Faculty of
Medicine, Tanta University and conformed to the Guide for
the Care and Use of Laboratory Animals published by the
US National Institutes of Health (NIH Publication No. 85-
23, revised 1996). Male albino rats (250–300 g) were housed
individually in metabolic cages under standard conditions with
free access to standard rat diet and drinking water ad libitum
throughout the study. They were acclimatized for one week
prior to the experiment, and all efforts were made to minimize
suffering.
2.2. Experimental CHF model: induction of ACF in rats
Under 40 mg/kg, of IP pentobarbital sodium anesthesia and
complete septic conditions, CHF was induced by volume over-
load achieved by creation of the infra renal ACF, using a nee-
dle technique (18-gauge needle, diameter 1.2 mm) as originally
described by Garcia and Diebold, 1990,9 and employed and
validated by many investigators.3,5,10ide, ularitide, alone or combined with Vasopeptidase inhibitor, Omapatrilat, on
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placed laterally and wrapped with normal saline-soaked steril-
ized gauze to retain moisture. The aorta and vena cava
between the levels of renal arteries and iliac bifurcation were
then exposed by blunt dissection of the overlaying adventitia.
A 2-cm section of the vessels distal to the origin of the renal
arteries was temporarily occluded (30 s) with a pair of
mini-clamps. At the midpoint between the two clamps, a 18-
gauge needle (Braun Melsungen, Melsungen, Germany) held
on a plastic syringe was inserted into the exposed abdominal
aorta and advanced into the vena cava through the common
wall between the vessels to create the shunt and manipulated
from side to side to widen the opening between the aorta
and vena cava. The needle was withdrawn. The aortic puncture
site was immediately sealed with a drop of cyanoacrylate glue
(Histoacryl, B. Braun GmbH, Tuttlingen, Germany), and the
clamp was removed 30 s later .Creation of a successful fistula
was confirmed visually by the pulsatile bright flow of oxy-
genated blood into and swelling of the vena cava. The intesti-
nes were repositioned and the abdominal cavity was closed by
absorbable suture. Post-surgical analgesia was provided by
metamizole (dipyrone, 40 mg/kg s.c.). Sham-operated rats
served as controls, underwent similar surgical procedures but
without puncture of the vessels or AC creation. After the sur-
gical procedure was completed (10 min), the rats were given
0.2 ml of 40,000 U/ml penicillin and allowed to recover and
then transferred to individual metabolic cages for daily moni-
toring of urinary sodium excretion (UNaV) and urinary output.
Seven days after the operation, the ACF rats were further
subdivided, on the basis of their daily (UNaV), into rats with
compensated (Com) CHF (moderate CHF, (UNaV)
> 1200 lEq/24 h) and sodium retaining rats with decompen-
sated (Decom) CHF (severe CHF, UNaV < 100 lEq/24 h).
10
Rats with UNaV greater than 100 lEq/24 h and less than
1200 lEq/24 h were not included in this study.
2.3. Experimental design and treatment protocols
One week after the infrarenal AC anastomosis, the surviving
rats from the ACF model and sham-operated groups were ran-
domly assigned, according to daily (UNaV), to one of two
treatment protocols, Com or Decom HF, each started one
week after ACF and continued for additional two weeks, dur-
ing which daily urinary volume and (UNaV) were obtained.
2.3.1. The first approach (Decom-HF protocol): the treatment
of acute Decom HF
This experimental protocol included the rats (n= 45) that
developed severe Decom HF and avid Na retention and expe-
rienced many of the symptoms commonly associated with
CHF, such as dyspnea, lethargy, pallor in the extremities,
and a reduction in appetite.11
These rats were subjected to ularitide or OMA/ularitide
treatments that continued for 14 day. The rats were randomly
allocated into the following groups: Sham operated control
group: received isotonic saline solution, IP as a vehicle. Decom-
pensated (Decom-ACF) group: received the same volume of
isotonic saline solution, IP. Ularitide treated Decom-ACF
group: received ularitide (INN: synthetic URO, CardioPep
Pharma GmbH, Hannover, Germany, supplied as lyophilized
powder, was dissolved in isotonic saline solution), in a dosePlease cite this article in press as: Abo El gheit RE Eﬀect of the renal natriuretic pept
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10.1016/j.ajme.2016.05.005of 12 lg/kg/d, IP.12 OMA/Ularitide treated Decom-ACF group:
received combined ularitide (12 lg/kg/d, IP) and OMA
(1 lmol/kg/d, IP). The OMA dose would result in maximal
ACE and NEP inhibition.13 OMA was purchased from Amer-
ican Custom Chemicals Corporation (Cat#167305-00-2, San
Diego, CA, USA).
2.3.2. The second approach (Com-HF protocol): the treatment
of mild Com HF
The Com HF rats (n= 45), which eventually returned to
sodium balance (UNaV > 1200 lEq/d) were included in this
treatment protocol for 14 days and randomly assigned to the
following groups: Sham-operated control group: received iso-
tonic saline solution, IP. Com-ACF group: received the same
volume of isotonic saline, IP. Ularitide treated Com ACF
group: received ularitide in a dose of 12 lg/kg/d, IP. OMA/
Ularitide treated Com ACF group: received combined ularitide
(12 lg/kg/d, IP) and OMA (1 lmol/kg/d, IP).
2.4. Sampling
At the end of the treatment protocols, the animals were anes-
thetized deeply by sodium pentobarbital (70 mg/kg, IP) and
killed by decapitation. Their chest was opened, and the blood
was obtained directly from the heart. Blood samples were col-
lected on ice, then divided and drawn into heparin and EDTA
tubes, centrifuged for 15 min at 3500 rpm and kept frozen at
20 C until assayed all at once.14 Plasma obtained from the
EDTA-containing blood tubes was stored until assay of
plasma ANP, cGMP and plasma renin activity (PRA), angio-
tensin II (AngII) and aldosterone, while the heparinized
plasma from the second tube was used for plasma Na and cre-
atinine assay.
Urine was collected on ice. Urine samples for cGMP anal-
ysis were heated to >90 C before storage. All samples from
each animal were assayed together to avoid inter assay vari-
ability. Urine samples which are centrifuged for 10 min at
7000 rpm then refrigerated until assayed for Na and creatinine.
2.5. Tissue weights
After decapitation, the heart, lung and liver were harvested
instantaneously, placed on absorbent paper to remove excess
blood, and wet weights were recorded. Wet to body weight
ratios for these tissues were then calculated to assess the degree
of the hypertrophy and congestion.15
2.6. Renal parameters
24 h urine samples were collected from all groups throughout
the experimental period to determine urine volume/24 h.
Plasma and urine Na+ concentrations were assessed by flame
photometry (Model FP 20 seac, Seac Radim Company, Italy)
with chemical kits (BioMe´rieux, France).
2.7. Hormonal and biomarkers assay
Plasma ANP,16 (PRA),17 Ang II,18 and aldosterone,19 were mea-
sured by radioimmunoassay. Plasma and urine cGMP levels20
were measured using an immunoradiometric assay kit suppliedide, ularitide, alone or combined with Vasopeptidase inhibitor, Omapatrilat, on
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Germany), according to the manufacturer’s protocol.
Plasma high-sensitivity cardiac troponin T (hs-cTnT) and N-
terminal pro–brain natriuretic peptide (NT-pro-BNP), as sensitive
and specific markers of myocyte injury and stress respectively,
were measured using sensitive enzyme-linked immunosorbent
assay (ELISA) kits (Boehringer Mannheim, Mannheim, Ger-
many) according to the manufacturer’s instructions.21 Plasma
cystin C concentrations, as a marker of kidney injury, were mea-
sured by using ELISA kit (R&D Systems, America).
2.8. Analytical methods
Urine flow rate (UFR) was calculated by the following for-
mula: UFR= UV/T  BW, where UV is the urine volume,
T is the time and BW is the body weight of the rat. Fractional
excretion of sodium (FENa) was calculated by CNa/GFR,
where CNa is the clearance of sodium. Clearance was calcu-
lated using the usual formula: Cx = Ux x UFR/Px, where,
Cx is the clearance of substance x and Px is the plasma concen-
tration of x.22 Glomerular filtration rate (GFR) was measured
as creatinine clearance (CLCR, ml/min) according to the
method described by Cameron and Gerger.23 CLCR was esti-
mated from SCr using the Cockroft–Gault equation.24 SCr
was measured by creatinine kit (Diamond diagnostic, Egypt)
based on the Jaffe´ reaction.25
Renal cGMP production was calculated as follows: renal
cGMP generation = (urinary flow  urinary cGMP concen-
tration)  (GFR  plasma cGMP concentration).26
2.9. Rat survival status
During the experimental periods, cages were inspected for
dead animals daily. The survival status and time of death of
the rats in each group were recorded for generation of the sur-
vival curves. The carcass was weighed and a gross postmortem
examination was performed. Postmortem examination
revealed that decompensated rats developed additional signs
of CHF, i.e. ascites, enlarged liver, lung congestion, and pleu-
ral effusions whereas these signs were mild or nonexistent in
compensated rats.-200
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Figure 1 The daily urinary sodium (UNa) excretion patterns in ACF
excretion in ACF rats. Values are mean ± SD. *p< 0.05 vs. Sham. Com
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Survival rate was analyzed by the Kaplan–Meier analysis using
the log-rank test with construction of survival curve. One-way
Analysis of variance (ANOVA) for repeated measurements
was performed followed by Bonferroni test for analysis of
data. All statistical analyses were performed using Graph-
Pad Prism software release 5.0 (Graph Pad Software, San
Diego, California, USA). A p value less than 0.05 was consid-
ered statistically significant.
4. Results
4.1. Daily sodium excretion patterns in ACF and sham-operated
controls rats (Fig. 1)
Before surgery, the daily UNa ranged between 1378 and
1843 lEq/24 h (mean = 1593) (on the basis of measurements
in 120 rats during 6 consecutive days before the operation).
All groups displayed an immediate postoperative decrement
in sodium excretion, most likely related to the anesthesia and
surgical stress. However, whereas in sham-operated rats the
decrease in UNa lasted for 24 h and then returned to the
presurgical base-line levels on the 2nd postoperative day.
Two distinctly different patterns of sodium excretion were evi-
dent in ACF rats. Approximately 43% of the animals dis-
played progressive sodium retention, as depicted by the
gradual decrease in UNa. These animals developed clinical
signs of CHF characterized by severe dyspnea and edema.
In compensated CHF rats, the UNa was significantly lower
in the 1st wk after the operation compared with sham-operated
animals. However, UNa increased progressively and returned
to normal Na balance (UNaV > 1200 lEq/24 h), within
7 days. These animals did not show symptoms indicative of
HF despite the presence of a patent ACF and the finding of
a hypertrophied heart when these rats were killed.
Thus, on the basis of the above findings, it was possible to
divide the ACF rats into two subgroups: animals that retained
sodium and developed manifestation simulating severe (acute)
decompensated HF and animals that compensated and*
*
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rats and in sham-operated controls. Two distinct patterns of UNa
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trolled chronic HF in human.
4.2. Effect of ularitide/OMA treatment on humeral profile in
ACF rats (Fig. 2)
The activity of RAAS is enhanced in correlation with the
severity of the cardiac dysfunction and provides a prognostic
index in most HF patients.2
Three weeks after shunt induction, all ACF rats displayed
significant activation of renin angiotensin system with sec-
ondary hyperaldosteronism. The PRA increased about 1.1 foldFigure 2 Effect of Ularitide/OMA treatment on humoral profile and
Ang II (B), aldosterone (C) and biomarkers of cardiac stress (ANP (D
mean ± SD. *p< 0.05 vs. Sham. yp< 0.05 vs. Com-ACF. #p< 0.05 v
vs. Ularitide treated Decom-ACF. Ang II; angiotensin II, ANP; atria
ACF; Aorto-caval fistula, cTnT; High-Sensitivity Troponin T, NT-p
OMA; omapatrilat.
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versus sham animals. The increased PRA resulted in increased
plasma Ang II level by 1.3 fold in Com-ACF compared to 2.6
fold in Decom-ACF versus sham and increased plasma aldos-
terone by about 1.1 fold in Com-ACF compared to 2.9 fold
increase in Decom-ACF versus sham control group.
It appears that the systemic RAAS activation is most pro-
nounced in acute Decom HF.
Ularitide treatment to Com-ACF rats resulted in significant
suppression in RAAS, an effect that is amplified by concomi-
tant OMA treatment to level comparable to that of sham
group. While ularitide treatment to Decom-ACF rats resultedbiomarkers of cardiac stress and injury: plasma renin activity (A),
), NT-proBNP (E)) and injury (cTnT (F), in ACF rats. Values are
s. Ularitide treated Com-ACF. @p< 0.05 vs. De-ACF. p< 0.05
l natriuretic peptide, Com; compensated, Decom; decompensated,
roBNP; N-terminal of the prohormone brain natriuretic peptide
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ularitide treatment resulted in dramatic suppression of RAAS
in the Decom group.4.3. Effect of ularitide and OMA on biomarkers of renal
(Table 2, Fig. 3) and cardiac injury and stress (Fig. 2)
Both the troponins and the NPs are gold standard biomarker
classes that share the unique feature of being secreted directly,
and almost exclusively, by cardiac tissue. Thus, they were pro-
posed as a diagnostic tool in the determination of the cardiac
dysfunctions and as a prognostic marker in the prediction of
the survival of the HF patients, even, more sensitive than that
obtained from imaging or even invasive hemodynamics.6Figure 3 Effect of ularitide/OMA treatment on plasma cyst –C (com
(compensated (C, E) and decompensated (D, F) ACF rats. The m
experimental group. *p< 0.05 vs. Sham. yp< 0.05 vs. Com-ACF. #p
p< 0.05 vs. Ularitide treated Decom-ACF. Com; compensated, Deco
CGMP; cyclic guanosine monophosphate, cyst –C; cystin C.
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compared to sham, reaching 3.4 fold in Com-ACF versus 6
fold increase in Decom-ACF rats. In spite of the dramatic
increase in ANP in the Decom group, the rats still retained
sodium.
With HF induction, the Com rats displayed a significant
increase in the indicator of the ventricular wall stress, NT-
proBNP 2.2 and 7 fold respectively in Com and Decom-
ACF rats respectively versus sham control group.
Ularitide treatment to ACF rats resulted in significant
reduction in ANP and NT-proBNP, an effect that is amplified
by concomitant OMA treatment to levels comparable to that
of sham group in Com.
In spite the Com-ACF animals had cTnT level comparable
to that of the sham group, a significant myocardial cell injurypensated (A) and decompensated (B), plasma and urinary CGMP
ean (horizontal line) and individual values are shown in each
< 0.05 vs. Ularitide treated Com-ACF. @p< 0.05 vs. De-ACF.
m; decompensated, ACF; Aorto-caval fistula, OMA; omapatrilat,
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Effect of the renal natriuretic peptide, ularitide 7was detected in Decom-ACF group as indicated by cTnT leak
into serum with significant elevation compared to the sham
group.
The ularitide treatment had an obvious cardio protective effect
which is marked by significant decrease in cTnT level and aug-
mented in OMA/ularitide compared to Decom-ACF group.
Cystin C as an endogenous marker of GFR, and renal
injury,27 was increased significantly with induction of HF in
ACF rats, exacerbated in Decom group. While it was
decreased markedly with ularitide treatment to ACF rats, it
was restored to normal levels with concomitant OMA and
ularitide treatment, implying renoprotective effect of ularitide
and OMA in our model.
4.4. Effects of ularitide and OMA on renal hemodynamics and
excretory functions (Table 2, Figs. 4A, B and 5A, B)
While the Com-ACF animals returned to normal UNa+ excre-
tion on 7th postoperative day, the Decom-ACF exhibited avidFigure 4a Effect of ularitide/OMA treatment on daily urinary volum
mean ± SD. *p< 0.05 vs. Sham, yp< 0.05 vs. Com-ACF, #p< 0.05 v
vs ularitide treated Decom –ACF Com; compensated, Decom; decom
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10.1016/j.ajme.2016.05.005Na retention throughout the experimental period, and deterio-
rated renal functions as indicated from increased plasma cystin
C level and decreased GFR compared to sham control group.
Similar differences between Com and Decom-ACF rats
were also observed in the urinary flow rate and FENa.
In Decom-ACF rats, plasma and urinary cGMP levels
increased slightly (1.7 and 1.1-fold respectively) compared with
the marked increase in the Com-ACF rats (2.9 and 1.3 respec-
tively) versus the sham control group. This level of CGMP in
Decom group not matched with the 6-fold increase in ANP versus
3.4-fold in Com-ACF, reflecting attenuated ANP in the Decom-
CHF rats, but it was closely paralleled by the RAAS over activity.
Our results pointed out to the significant differences in
renal responses to ularitide in Com versus Decom-ACF rats,
as suggested from the differential natriuretic and diuretic
response between the two subgroups of ACF rats compared
to the sham control.
Rats with Com-ACF in which ularitide was administered
displayed a significantly natriuretic and diuretic responsee (A, B) in Comp and Decomp ACF rats respectively. Values are
s. Ularitide treated Com-ACF, @p< 0.05 vs. De-ACF. p< 0.05
pensated, ACF; Aorto-caval fistula, OMA; omapatrilat.
ide, ularitide, alone or combined with Vasopeptidase inhibitor, Omapatrilat, on
apatrilat in Congestive Heart Failure), Alex J Med (2016), http://dx.doi.org/
Figure 4b Effect of ularitide/OMA treatment on daily absolute Na excretion (A, B), in Comp and Decomp ACF rats respectively.
Values are mean ± SD. *p< 0.05 vs. Sham. yp< 0.05 vs. Com-ACF. #p< 0.05 vs. Ularitide treated Com-ACF. @p< 0.05 vs. De-ACF.
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8 R.E. Abo El gheitcompared with Com-ACF rats, that received vehicle only. This
response maximized with OMA treatment to levels statistically
elevated compared to sham group.
The diuretic and natriuretic effect of both ularitide and
OMA was accompanied by parallel effects on GFR, FENa
excretion, CGMP with preserved renal functions.
Ularitide treatment to Decom-ACF rats induced significant
but limited natriuretic effect failed to restore normal level of
Na excretion.
The blunted response to urodilatin in the Na-retaining
animals was associated with a marked increase in PRA
and plasma aldosterone levels compared to sham control
rats.
To gain a more detailed insight in the possible role of the
attenuated response of ularitide in decompensated stage of
CHF, in spite of the relative resistance to degradation by
NEP, the OMA was administered.
The dual ACE and NEP inhibition by OMA, restored the
renal response to ularitide treatment and significantly
improved the natriuretic/diuretic action of ularitide in
Decom-ACF rats, as represented by dramatic increase in
UNa, FENa excretion, GFR, urinary flow rate and significant
improvement in renal function. The improvement in the ular-
itide’ natriuretic and diuretic response after OMA treatment
was associated with a suppression of the previously elevated
plasma aldosterone.Please cite this article in press as: Abo El gheit RE Eﬀect of the renal natriuretic pept
experimental volume overload-induced congestive heart failure in rats (Ularitide/O
10.1016/j.ajme.2016.05.005The present study suggests that increased activity of the
RAAS may serve as important determinant factor in renal
Na handling. This notion is further supported by the demon-
stration that OMA administration led to an impressive natri-
uresis in the Decom-ACF rats with Na retention converting
them into animals that compensated and returned to normal
sodium balance. Thus renal responsiveness to NPs in this
experimental model of HF appears to be greatly influenced
by the activity of the RAAS.4.5. Effect of ularitide/OMA on body, organs weights (Table 1)
in ACF rats
Both lung weight (LW) and heart weight (HW) versus body
weight (BW) were used as indices of pulmonary congestion
and cardiac hypertrophy, generally considered as two indices
of the HF severity. While liver weight to BW was used as an
index of systemic congestion.28
With the surgical induction of HF, the Decom-ACF rats
exhibited significant decrease in their BW compared to sham.
Total and relative heart weights were elevated in rats with
Comp-ACF (49.7%, 48.9%) and increased further in
Decom-ACF (106.9%, 109.4%) versus sham rats, respectively.
In the Decom-ACF rats, the total and relative lung weights
were increased by 83.6% and 85.1%. Similarly the total andide, ularitide, alone or combined with Vasopeptidase inhibitor, Omapatrilat, on
mapatrilat in Congestive Heart Failure), Alex J Med (2016), http://dx.doi.org/
Figure 5a Effect of ularitide/OMA treatment on GFR (A, B), in Com and Decom ACF rats respectively .Values are mean ± SD.
*p< 0.05 vs. Sham. yp< 0.05 vs. Com-ACF. #p< 0.05 vs. Ularitide treated Com-ACF. @p< 0.05 vs. De-ACF. p< 0.05 vs. Ularitide
treated Decom-ACF. GFR; glomerular filtration rate, FNa; fractional Na excretion, Com; compensated, Decom; decompensated, ACF;
Aorto-caval fistula, OMA; omapatrilat.
Effect of the renal natriuretic peptide, ularitide 9relative liver weights were increased by 17.6% and 19.1%
respectively.
Although the total and relative lung and liver weights, in
Com-ACF rats were comparable to those of the sham group,
the Decom-ACF group had marked cardiac hypertrophy, pul-
monary and liver congestion confirming decompensated HF.
Ularitide treatment to the Comp-ACF rats blocked the
development of cardiac hypertrophy to level comparable to
that of both OMA/ularitide and sham rats, while ularitide
treatment of Decom-ACF attenuated these HF induced patho-
logical changes with 27.9% reduction in the relative HW, max-
imized by concomitant OMA/ularitide treatment to 48.6%
reduction.
It is evident from our results that ularitide treatment results
in significant attenuation of both pulmonary and systemic con-
gestion as denoted from decreased lung and liver weighs/body
weight ratios. An effect was amplified by OMA treatment.
4.6. Effect of ularitide and OMA on cumulative survival curves
(Fig. 6), in ACF rats
The ACF procedure was associated with 13% early (67 days)
mortality, occurring mostly within the first 48 h, and these ani-
mals were excluded from all analyses.
One hundred and five animals survived the perioperative
period and entered the study.Please cite this article in press as: Abo El gheit RE Eﬀect of the renal natriuretic pept
experimental volume overload-induced congestive heart failure in rats (Ularitide/Om
10.1016/j.ajme.2016.05.005In sham control and OMA/ularitide treated Com-ACF
groups, survival was 100% (15/15) till termination of study.
In Com-ACF and ularitide treated Com-ACF groups, the sur-
vival was 73% (11/15) and 93% (14/15) respectively, while in
Decom-ACF, the survival was dramatically reduced to
0.47% (7/15) to be improved in ularitide treated Decom-
ACF to 73% (11/15) and markedly elevated with both
OMA/ularitide treatment of Decom-ACF rats to about 93%
(14/15).
The dual inhibition of both (ACE) and NEP together with
ularitide improved survival rate even more in ACF rats.
5. Discussion
The primary objectives in the treatment of patients with HF
are to improve quality of life and increase survival. Adminis-
tration of NPs and maneuvers that enhance or restore their cel-
lular actions or prevent their degradation continues to be
evaluated for therapeutic efficacy in HF.
A major goal of the present study has been to evaluate the
efficacy of ularitide and OMA29, two of the most promising
agents currently being studied, in ACF induced CHF, under
different condition of compensation.
Similar to previous studies,29,30 ACF induction in the pre-
sent study produced the broad neurohormonal activation,
sodium-retaining hallmarks of CHF, with reduced renalide, ularitide, alone or combined with Vasopeptidase inhibitor, Omapatrilat, on
apatrilat in Congestive Heart Failure), Alex J Med (2016), http://dx.doi.org/
Figure 5b Effect of ularitide/OMA treatment on FNa (A, B), in Com and Decom ACF rats respectively .Values are mean ± SD.
*p< 0.05 vs. Sham. yp< 0.05 vs. Com-ACF. #p< 0.05 vs. Ularitide treated Com-ACF. @p< 0.05 vs. De-ACF. p< 0.05 vs. Ularitide
treated Decom-ACF. GFR; glomerular filtration rate, FNa; fractional Na excretion, Com; compensated, Decom; decompensated, ACF;
Aorto-caval fistula, OMA; omapatrilat.
Table 1 Effect of ularitide and OMA on body and organ weights in ACF-induced CHF rats.
Sham Com-ACF Decom-ACF
Com-ACF Ularitide
treated
Ularitide/OMA
treated
Decom-ACF Ularitide
treated
Ularitide/OMA
treated
BW(g) 269.2 ± 4.237 270.8 ± 3.584 271.5 ± 2.461 *#267 ± 8.595 *265.9 ± 6.222 268.4 ± 3.859 @270 ± 3.5
HW(mg) 713.90 ± 4.771 *1068.70 ± 8.538 y*745.8 ± 5.653 *y#708.3 ± 6.832 *1477 ± 15.364 *@1073.1 ± 8.925 *@769.8 ± 9.473
HW/BW(mg/g) 2.652 ± 0.086 *3.950 ± 0.079 y2.75 ± 0.041 y2.65 ± 0.077 *5.55 ± 0.414 *@4 ± 0.172 *@2.85 ± 0.0527
Lung Wt.(mg) 973.4 ± 9.559 1047.2 ± 19.559 993.9 ± 5.82 980.9 ± 6.734 *1787.6 ± 28.39 *@1211.1 ± 17.05 *@995.7 ± 7.818
Lung Wt./BW
(mg/g)
3.619 ± 0.165 3.87 ± 0.845 3.66 ± 1.536 3.67 ± 0.092 *6.7 ± 0.083 *@4.5 ± 0.199 @3.69 ± 0.145
Liver wt.(mg) 8206 ± 30.42 8215.8 ± 39.34 8203.3 ± 44.96 8109.4 ± 49.3 *9651.7 ± 152.88 *@8892.1 ± 43.46 *@8282.2 ± 84.875
Liver wt./BW
(mg/g)
30.48 ± 1.50 30.34 ± 2.871 30.21 ± 2.176 30.37 ± 2.184 *36.3 ± 2.533 *33.1 ± 1.849 @30.67 ± 1.119
ACF; aortocaval fistula; BW, Body weight; HW, Heart weight; Wt, wet weight. Com; compensated, Decom; decompensated, ACF; Aorto-caval
fistula, OMA; Omapatrilat. CHF; congestive heart failure. Values are mean ± SD.
*p< 0.05 vs. Sham. yp< 0.05 vs. Com-ACF. #p< 0.05 vs. Ularitide treated Com-ACF.
@p< 0.05 vs. De-ACF. p< 0.05 vs. Ularitide treated Decom-ACF.
10 R.E. Abo El gheitfunction, elevated relative organs weights and biomarkers of
organ injury, that were more evident in Deco-ACF rats.
Similar to our results with ACF induction, the rats are clas-
sified to Com and Decom, and most HF patients maintain nor-
mal Na balance when maintained on low salt diet, but about
50% developed positive Na balance when fed a normal salt
diet. These differences between Com- and Decom-CHFPlease cite this article in press as: Abo El gheit RE Eﬀect of the renal natriuretic pept
experimental volume overload-induced congestive heart failure in rats (Ularitide/O
10.1016/j.ajme.2016.05.005patients or animals are probably due to major differences in
their hormonal status.31
A common feature of both the CHF patients and experimen-
tal animals with sodium retention10,29,31 and the Decom-rats with
ACF in the present study was the activation of the RAAS.
It is now abundantly clear that despite early activation of
the RAAS in CHF is considered as a counter-regulatoryide, ularitide, alone or combined with Vasopeptidase inhibitor, Omapatrilat, on
mapatrilat in Congestive Heart Failure), Alex J Med (2016), http://dx.doi.org/
Figure 6 The Kaplan–Meier survival plot, of 14 days survival among 87 rats classified into sham (n= 15, solid red line), com-ACF
(n= 11, solid green line), decom (n= 7, solid green line), ularitide treated com-ACF (n= 14, thick dotted black line), ularitide treated
decom-ACF (n= 11, thick dotted black line), OMA/ularitide treated comACF (n= 15, thick dotted blue line), OMA/ularitide treated
decom-ACF (n= 14, thick dotted blue line). Significant improvement in survival rate was found by log-rank test in ularitide and OMA/
ularitide treated com and decom groups compared to com and decom-ACF groups respectively (P< 0.05). Com; compensated, Decom;
decompensated, ACF; Aorto-caval fistula, OMA; omapatrilat.
Effect of the renal natriuretic peptide, ularitide 11response directed at maintaining renal and major body organ
perfusion, numerous studies implicate persistent RAAS activa-
tion in the derangement of renal and cardiac function, by
enhancement of systemic vasoconstriction, promotion of other
neurohormonal systems such as AVP and salt and water reten-
tion by the kidney, in addition to its direct deleterious actions
on the myocardium.32
The significant elevation of ANP observed in our study
with the Com-ACF group that accentuated with the Decom-
ACF, considered to be a hallmark of neurohumoral activation
in CHF. This is consistent with previous data concluded that
NPs concentrations are correlated with the degree of hemody-
namic compromise and their high concentrations predict poor
long-term survival.33 The elevated ANP plasma levels in ACF
induced HF groups mostly attributed to enhanced synthesis
and release of the hormone, not only by atria but also by
recruitment of ventricular myocytes induced by volume load-
ing4 rather than decreased clearance.34
The elevated ANP is viewed as an important adaptive
mechanism that helps unload the failing myocardium.4 The
importance of the NPS in the CHF is further underscored by
key studies demonstrated that elimination of the NP action
via the use of the ANPR blocker or genetic deletion35 or sur-
gical removal of atrium, disrupts cardiac performance and
renal responses to volume loading and induces Na retention
in experimental HF models.6 Conversely increased circulation
of the NPs by IV administration has been shown to improve
general clinical status, with improved cardiac and renal
functions.36
In spite of the remarkable activation of NP system in Com
and Decom-ACF rats and the ability of NPs to counter the
effects of the vasoconstrictor/antinatriuretic system, the two
groups differed markedly in their renal responses with the
Decom-ACF group displayed the salt and water retention,
suggesting emergence of renal resistance to ANP, as docu-
mented from the attenuated plasma level and renal cGMPPlease cite this article in press as: Abo El gheit RE Eﬀect of the renal natriuretic pept
experimental volume overload-induced congestive heart failure in rats (Ularitide/Om
10.1016/j.ajme.2016.05.005production and this could represent a critical turning point
in the development of salt retention, edema formation and
progression from a compensated to a decompensated state in
CHF.2
The exact mechanisms that mediate the renal resistance to
NPs in overt CHF most likely are multifactorial. It is probable
that activation of the renin-angiotensin axis may overcome the
natriuretic effects of ANP. The markedly elevated Ang II
observed in Decom-ACF rats, appears to impede the action
of ANP by altered ANP intracellular transduction signal via
reduced production of cGMP, or increased cGMP degradation
by Ang II induced upregulated renal cGMP Phosphodiesterase
(PDE) activity,37or inducing downregulation of the ANPRs,
aggravated by the chronically elevated plasma ANP levels.4,10
It has been demonstrated that the expression and activity of
the NEP are enhanced in experimental models of HF with
accelerated NP degradation and decreased renal ANP avail-
ability.38 This decreased responsiveness leads to enhanced local
actions of Ang II and the sympathetic nervous system in the
kidney, resulting in salt retention and further deterioration
of cardiac function.4
The renal resistance to ANP could be explained by the pos-
sible appearance of abnormal circulation and inadequate
secretory reserve of NPs associated with the decompensated
HF.39 This was supported by Bialik et al.,30 who demonstrated
significant alterations in the normal maturation of the NP
granules and accelerated premature release of the hormonal
content into the circulation only in the decompensated ACF
rats, while they were comparable in compensated ACF and
sham control groups.
The impaired renal functions with induction of HF, as
reflected from reduced GFR observed in ACF rats, are consis-
tent with the results obtained previously in experimental HF
models.40 The mechanisms responsible for the high prevalence
of renal dysfunction in HF populations are complex. It is
attributed mostly to marked increased renal vascular resistanceide, ularitide, alone or combined with Vasopeptidase inhibitor, Omapatrilat, on
apatrilat in Congestive Heart Failure), Alex J Med (2016), http://dx.doi.org/
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ide/Oand reduction in renal blood flow (RBF) as a consequence of
the forward failure with reduction in the cardiac output,41
while several reports suggested increased venous pressure to
be the culprit hemodynamic lesion to account for worsening
renal function in chronic advanced HF patients.42
The Ang II mediated increase in the efferent arteriolar resis-
tance is critical for preservation of the GFR in the presence of
reduced RBF. Because of the intense efferent arteriolar vaso-
constriction, further compensation isn’t possible if RPP falls
as a result of systemic hypotension, causing sharp decline in
GFR.43 Secondary to the altered glomerular function and as
a direct response to neurohumoral changes, the fractional
reabsorption of filtered Na increased at the level of proximal
tubule. Similarly in distal tubule and collecting ducts, the ele-
vated Ang II and aldosterone levels, respectively, enhance
activities of the NacL co-transporter and the distal Na+ chan-
nel (ENac).44
In the Com-ACF rats as well as in the initial compensated
phase of HF patients, the maintenance of the Na balance has
been attributed in part to elevated NP levels. While, the
Decom-ACF rats displayed Na and water retention despite
the expansion of the ECF and the full activated NPs. The
blunted natriuresis appears to be attributed to hemodynamic,
neural alterations in HF and largely determined by the balance
between two antagonistic hormonal systems: RAAS and ANP,
rather than the action of a single system, where the signals
from several opposing as well as synergistic systems integrated
in the kidney to promote abnormal sodium and water
reabsorption.45
The plasma concentrations and urinary excretion of the sec-
ond messenger, cGMP were significantly elevated in Com-
ACF group as its levels correlate well with ANP-induced natri-
uresis and diuresis.46 While in the Decom-ACF rats, its levels
failed to parallel the marked increase in ANP level. This is con-
sistent with previous studies in overt experimental and human
CHF,37 reported that the NP/cGMP signaling pathways are
impaired with attenuated glomerular and urinary cGMP excre-
tory capacity due to renal resistance to ANP and that such
impairment may contribute to the progression of cardiorenal
dysfunction in CHF.
Our results revealed marked improvement in the renal func-
tions in ACF rats treated with ularitide accompanied by
marked natriuresis and diuresis. The favorable renal effects
of ularitide are probably due to both renal hemodynamic
and direct tubular actions.47
Besides increasing RBF through vasodilation of the renal
vasculature, ularitide stimulates dilatation of afferent and con-
striction of efferent renal arterioles, leading to increased
glomerular hydrostatic pressure and glomerular filtration. Fur-
thermore the ularitide inhibits the Ang II-induced mesangial
cell contraction via the accumulation of cGMP leading to
mesangial cells relaxation thereby increases the effective sur-
face area for filtration thus increasing the ultrafiltration coeffi-
cient. GFR improved more by inhibiting tubuloglomerular
feedback.47
Moreover, the ularitide has direct tubular actions, through
acting in a paracrine mechanism. It can inhibit Ang II-
stimulated sodium and water transport in proximal convoluted
tubules. In cortical collecting ducts, it inhibits tubular water
transport by antagonizing the action of vasopressin.5
The increase in cGMP in ACF rats especially Com group
reflects the action of ularitide on guanylate cyclase-coupledide, ularitide, alone or combined with Vasopeptidase inhibitor, Omapatrilat, on
mapatrilat in Congestive Heart Failure), Alex J Med (2016), http://dx.doi.org/
Effect of the renal natriuretic peptide, ularitide 13receptors in the vessels and the kidneys. Perhaps ularitide stim-
ulates both luminal and basolateral receptors, increasing the
intracellular cGMP level, which reduce apical Na+-channel
activity either by binding directly to the amiloride-sensitive
cation channel or by stimulating cGMP-dependent protein
kinase.46
With the increased GFR observed with ularitide, one may
speculate that this resulted in the greatest amount of ularitide
being filtered from the plasma and presented to renal tubules,
resulting in the greatest increase in urinary cGMP excretion
and natriuresis.
In accordance with our results, ularitide treatment of
ACF-induced HF rats10,12 and dogs46,48 models, demonstrated
significant dose-dependent increases in urinary flow, GFR,
urinary sodium and cGMP excretion with improved hemody-
namic parameters.
Of special interest is our finding that ularitide given to the
Decom HF rats induced mild but significant natriuretic and
diuretic responses with improved GFR, while the endogenous
ANP failed in spite of its marked elevation. This may be
explained by the fact that ularitide exhibited higher resistance
to NEP, which is located mainly in the brush border of the
proximal tubule. Thus, in contrast to ANP, ularitide is more
likely to reach the inner medullary collecting duct to bind to
the NPR-A and inhibits sodium reabsorption.5 Moreover
these results imply that ANP refractoriness in Decom group
may not be simply due to downregulation or reduced affinity
of NPR-A receptor, given that ularitide as an agonist to this
receptor possesses more potent actions.
Indeed studies evaluating the effects of ularitide in ADHF
patients (SIRIUS I49 and SIRIUS II50) have shown favorable
effects on hemodynamic, neurohumoral and symptomatic pro-
files accompanied by a steep increase in cGMP without any
compromise in renal function despite a modest and dose-
dependent decrease in BP. Moreover, a larger Phase III trial
is currently ongoing, evaluating the efficacy and safety of ular-
itide in ADHF patients (TRUE-AHF).5
Indeed, dual ACE and NEP enzyme inhibition with OMA
treatment in Com group maximizing ularitide’ beneficial
effects, while restoring renal effect of ularitide in the Decom-
ACF group, resulted in a dramatic natriuresis, associated with
a suppression of the previously elevated plasma RAAS,
demonstrating that when the influence of the RAAS is
removed the natriuretic effects of NPs may be expressed.
The favorable effects obtained with concomitant OMA/
ularitide treatment of ACF groups, could be attributed to
ACE I by OMA, reversing the previously mentioned deleteri-
ous Ang II induced renal effects,4,10,32 leading to drastic natri-
uresis, diuresis, and improved renal functions observed in ACF
rats.
The favorable renal actions of OMA could be explained in
part by enhancing the NPs via its NEP-inhibiting properties,
as indicated by the markedly increased urinary cGMP excre-
tion and confirmed by previous in vivo studies reported that
the cardiorenal actions of OMA mediated in part by endoge-
nous NPs, and were markedly attenuated by a NPR-
antagonist.13
Previous studies of experimental model13,51,52 and clinical
trials8,53of CHF, have reported that OMA was superior to
selective NEP inhibitor, or the ACE inhibitor, in promoting
Na excretion, GFR, reduced the afterload, myocardial wall
stress and improved cardiac function. In the IMPRESS (Inhi-Please cite this article in press as: Abo El gheit RE Eﬀect of the renal natriuretic pept
experimental volume overload-induced congestive heart failure in rats (Ularitide/Om
10.1016/j.ajme.2016.05.005bition of Metalloproteinase in a Randomized Exercise and
Symptoms Study in Heart Failure) trial,54 OMA was well tol-
erated, and led to a better clinical status and lower incidence of
the combined mortality/morbidity end point compared with
lisinopril, with preserved renal functions.
The lack of increase in plasma ANP after OMA administra-
tion was probably due to hemodynamic improvement.51
Given that the NEP degrades other vasodilator peptides,39
we cannot exclude the role of these peptides in the potentiated
effects of OMA in the CHF group.
Plasma and urinary CGMP, a marker of the renal activity
of the NPs increased significantly in the Com-ACF group with
ularitide and further accentuated with OMA.
The increased plasma and urinary CGMP levels observed in
OMA/ularitide treated Decom-ACF rats, confirmed OMA’s
efficiency in NEP inhibition, reflected enhanced sensitivity
and potentiated effects of NPs, with accumulation of CGMP,
possibly through blocking the Ang II mediated increases in
intracellular PDE, that impair NP mediated increases in
cGMP.39
When the heart fails to balance VR with CO, the decom-
pensation occurs, that is confirmed through marked cardiac
hypertrophy and injury together with systemic and pulmonary
congestion, contributing to increased morbidity and mortal-
ity.2 However the congestion may be driven predominantly
by impaired renal reserve rather than by progressive cardiac
insufficiency.43
The cardiac hypertrophy that accompanies HF, is initially
compensatory for an increased work load; however, prolonged
hypertrophy can become detrimental, and constitute a major
component of cardiac decompensation and severe injury and
a major risk factor for morbidity and mortality.32 It occurs
in response to a wide variety of hemodynamic and humeral
stimuli triggered by elevated Ang II which exerted a mechani-
cal stress on myocardium due to the systemic Ang II – medi-
ated increase in the afterload and mediated by local Ang II,
further aggravated by the aldosterone that acts directly on
the myocardium, inducing the structural remodeling of the
interstitial collagen matrix.55
Concerning the obtained antihypertrophic effect of ulari-
tide, that was enhanced by OMA in ACF rats, it may be sec-
ondary to improvement of the hemodynamic status by
reducing the pre- and afterload due their potent diuretic effect,
and mediated by RAAS suppression and enhanced NPs/GC-
A/cGMP/protein kinase type I signaling that negatively regu-
lates cardiac hypertrophy via inhibition of CYP11B2 (aldos-
terone synthase) mRNA expression and the calcineurin-
nuclear factor of activated T cells signaling pathway.56,57
The role of ongoing myocardial injury in HF has been
established with a strong association between elevated tro-
ponin levels and poor clinical outcomes.58 Similar to previous
results,15,38 the CHF induction, induced mild elevation of
cTnT, in Com-ACF that exacerbated in Decom-ACF group,
which may be related to hemodynamic and/or neurohormonal
abnormalities.21
Ularitide and OMA treatment was associated with reduc-
tion of biomarkers indicative of myocardial and renal injury.
Consistent with previous results decreased plasma NT-
proBNP concentrations observed in ularitide39 and OMA8
treated ACF groups, secondary to improve hemodynamic
and reflect reduced cardiac filling pressures that lower ventric-
ular wall stress.ide, ularitide, alone or combined with Vasopeptidase inhibitor, Omapatrilat, on
apatrilat in Congestive Heart Failure), Alex J Med (2016), http://dx.doi.org/
14 R.E. Abo El gheitIn the Decom-ACF rats, backward failure was evident with
increased liver and lung weights to BW, indicating systemic
and pulmonary congestion, associated with disease severity.28
Of special interest in our study, ularitide/OMA treatment
was able to manage congestion effectively, as shown not only
by the significant reduction in relative organ weights but also
by the reduction of NPs levels.
It is probable that the prevention of organ damage, relief
from congestion and preserved renal functions may be associ-
ated with lower mortality of ACF rats, when treated with ular-
itide and OMA.
6. Conclusion
Treatment of ACF rats with both ularitide and OMA consid-
erably improved the animals’ survival rate and inhibited the
development of renal dysfunction and organ injury. These pro-
tective actions were associated with significant suppression of
the RAAS with simultaneous unmasking and potentiation of
the NPs effects. So they may become therapeutic options to
improve the health status and clinical outcomes of patients
with CHF especially acute decompensated stage.
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